Reaction

Hepatitis B Reactivation reporting signals

Last recalculated 2026-09-14T18:28:35.993900+00:00 · 3,137 reports · 111 co-occurring drugs

As of the last recalculation, Hepatitis B Reactivation appears in 3,137 FAERS reports alongside 111 co-occurring drug terms. The strongest observed disproportionality signal is LAMIVUDINE ORAL (PRR 118.0).

Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.

Drug	Co-reports	PRR	ROR
Lamivudine Oral	394	118.0	119.9
Entecavir	167	100.2	101.6
Lamivudine	400	98.3	99.6
Bleomycin Sulfate	107	71.1	71.9
Tenofovir Disoproxil Fumarate Tablets	87	68.7	69.4
Doxorubicin	606	55.7	56.1
Doxorubicin Hydrochloride	239	52.5	52.9
Sofosbuvir	137	48.1	48.5
Vincristine Sulfate	194	46.8	47.1
Rituximab	930	41.1	41.2
Cyclophosphamide Injection, Solution	791	39.3	39.5
Cyclophosphamide	791	39.3	39.5
Cyclophosphamide For Injection	791	39.3	39.5
Bendamustine Hcl	73	32.0	32.1
Tenofovir Disoproxil Fumarate	137	28.7	28.8
Cabotegravir	30	24.9	25.0
Thiotepa	32	22.5	22.5
Etoposide	215	20.8	20.8
Melphalan	67	19.9	20.0
Melphalan Hydrochloride	67	18.1	18.1
Bendamustine Hydrochloride	31	17.3	17.4
Prednisolone	410	17.2	17.2
Prednisolone Oral	410	17.2	17.2
Prednisolone Oral Solution	410	17.2	17.2
Fludarabine Phosphate	91	15.8	15.8
Polatuzumab Vedotin	22	15.1	15.1
Ifosfamide	48	15.0	15.1
Ribavirin	126	13.5	13.5
Busulfan	31	13.2	13.2
Ledipasvir And Sofosbuvir	37	12.9	12.9
Cytarabine	102	11.6	11.6
Carfilzomib	45	10.7	10.7
Obinutuzumab	26	10.6	10.6
Docetaxel Anhydrous	104	10.6	10.6
Docetaxel	104	10.6	10.6
Prednisone	627	10.1	10.1
Trastuzumab	100	10.0	10.0
Ritonavir 100 Mg	22	9.8	9.8
Paclitaxel (Aibumin-Bound)	117	9.8	9.8
Everolimus Tablets	24	9.6	9.6
Basiliximab	15	8.5	8.5
Paclitaxel	122	8.5	8.5
Dexamethasone 1.5 Mg	329	8.2	8.2
Bictegravir Sodium, Emtricitabine, And Tenofovir Alafenamide Fumarate	22	8.1	8.1
Dexamethasone	329	8.1	8.1
Mycophenolate Mofetil	147	7.5	7.5
Mycophenolate Mofetil Hydrochloride	147	7.5	7.5
Mycophenilic Acid	23	7.4	7.4
Imatinib	19	7.2	7.2
Temozolomide	22	7.0	7.0
Cisplatin	80	6.9	7.0
Bortezomib	91	6.9	6.9
Velpatasvir And Sofosbuvir	13	6.7	6.8
Dolutegravir Sodium	9	6.6	6.6
Darunavir	15	6.6	6.6
Acalabrutinib	12	6.6	6.6
Ganciclovir	10	6.5	6.5
Ganciclovir Sodium	10	6.3	6.3
Baricitinib	9	6.2	6.2
Ritonavir	27	6.2	6.2
Alpelisib	8	6.1	6.1
Bevacizumab	109	6.0	6.0
Febuxostat Tablets 40 Mg	9	5.9	5.9
Febuxostat Tablets 80 Mg	9	5.9	5.9
Emtricitabine And Tenofovir Alafenamide	10	5.9	5.9
Alemtuzumab	17	5.9	5.9
Tacrolimus Ointment 0.1%	106	5.8	5.8
Tacrolimus Extended-Release Capsules	106	5.8	5.8
Mesna Injection	7	5.6	5.6
Mesna	7	5.5	5.5
Mycophenolic Acid	26	5.4	5.4
Abatacept	108	5.3	5.3
Dexamethasone Sodium Phosphate	8	5.2	5.2
Hydroxychloroquine	58	5.2	5.2
Daratumumab	31	5.2	5.2
Tofacitinib Citrate	10	5.1	5.1
Methotrexate Sodium	336	5.0	5.0
Anti-Thymocyte Globulin (Rabbit)	6	4.9	4.9
Tacrolimus	112	4.9	4.9
Mercaptopurine	12	4.6	4.6
Regorafenib	8	4.6	4.6
Blinatumomab	7	4.5	4.5
Ibrutinib	52	4.3	4.3
Glecaprevir And Pibrentasvir	7	4.2	4.2
Ofatumumab	21	4.2	4.2
Raltegravir	10	4.0	4.0
Brentuximab Vedotin	6	3.9	3.9
Carboplatin	70	3.7	3.7
Golimumab	47	3.7	3.7
Febuxostat	9	3.6	3.6
Everolimus	26	3.4	3.4
Gemcitabine	20	3.4	3.4
Thalidomide	18	3.3	3.3
Gemcitabine Hydrochloride	24	3.0	3.0
Oxaliplatin	33	3.0	3.0
Gefitinib	4	2.9	2.9
Fluorouracil Cream, 0.5%	33	2.9	2.9
Fluorouracil	33	2.8	2.9
Venetoclax	25	2.7	2.7
Elvitegravir, Cobicistat, Emtricitabine, And Tenofovir Alafenamide	4	2.6	2.6
Azacitidine For	7	2.6	2.6
Ruxolitinib	27	2.5	2.5
Belimumab	11	2.3	2.3
Atezolizumab	13	2.2	2.2
Bosutinib	3	2.2	2.2
Nivolumab	31	2.1	2.1
Crizotinib	4	2.1	2.1
Osimertinib	10	2.1	2.1
Axicabtagene Ciloleucel	3	2.0	2.0
Pomalidomide	26	1.7	1.7
Lenalidomide	100	1.6	1.6

Related reactions

Data source: openFDA FAERS. See the OpenPV methodology and limitations.